Corporate calendar for Boundless Bio, Inc. (BOLD): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | ||
| 2026-09-14 | $159M | |
| 2026-09-14 | $0.06 | $3M |
| 2026-09-14 | ||
| 2026-09-14 | $-0.03 | $278M |
| 2026-09-14 | $898M |
Price
| Price | $2.82 |
| Market Cap | $63M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 13 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (1-5) | 0.25 |
Related companies: ANTX · INTS · ITRM · NXTC · PLUR · PSTV · QTTB
Explore sector: Healthcare · Biotechnology
More sections of BOLD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks